Substance / Medication

Valbenazine

Overview

Active Ingredient
valbenazine
RxNorm CUI
1918219

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
1
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia.
Giri Nagdeep, Jimenez Roland, Rees Linda et al. · Clin Transl Sci · 2025
PMID: 41215526RCTFull text (PMC)
A Model-Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia.
Nguyen Hoa Q, Kuan Han-Yi Steve, Crass Ryan L et al. · J Clin Pharmacol · 2024
PMID: 39051716RCT
Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers.
Chung Woo Kyung, Hwang Inyoung, Kim Byungwook et al. · Clin Transl Sci · 2023
PMID: 36514192RCTFull text (PMC)
The effects of valbenazine on tardive dyskinesia in older and younger patients.
Sajatovic Martha, Alexopoulos George S, Burke Joshua et al. · Int J Geriatr Psychiatry · 2020
PMID: 31617235RCTFull text (PMC)
The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
McIntyre Roger S, Calabrese Joseph R, Nierenberg Andrew A et al. · J Affect Disord · 2019
PMID: 30583148RCT
Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.
Correll Christoph U, Cutler Andrew J, Kane John M et al. · J Clin Psychiatry · 2018
PMID: 30695293RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Valbenazine (substance)
SNOMED CT
733727001
UMLS CUI
C4078701
RxNorm CUI
1918219

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.